Display options
Cite
Hosseini M, Karami Z, Janzadenh A, et al. The Effect of Intrathecal Administration of Muscimol on Modulation of Neuropathic Pain Symptoms Resulting from Spinal Cord Injury; an Experimental Study. Emerg (Tehran). 2014;2(4):151-7
Hosseini, M., Karami, Z., Janzadenh, A., Jameie, S. B., Haji Mashhadi, Z., Yousefifard, M., & Nasirinezhad, F. (2014). The Effect of Intrathecal Administration of Muscimol on Modulation of Neuropathic Pain Symptoms Resulting from Spinal Cord Injury; an Experimental Study. Emergency (Tehran, Iran), 2(4), 151-7.
Hosseini, Marjan, et al. "The Effect of Intrathecal Administration of Muscimol on Modulation of Neuropathic Pain Symptoms Resulting from Spinal Cord Injury; an Experimental Study." Emergency (Tehran, Iran) vol. 2,4 (2014): 151-7.
Hosseini M, Karami Z, Janzadenh A, Jameie SB, Haji Mashhadi Z, Yousefifard M, Nasirinezhad F. The Effect of Intrathecal Administration of Muscimol on Modulation of Neuropathic Pain Symptoms Resulting from Spinal Cord Injury; an Experimental Study. Emerg (Tehran). 2014;2(4):151-7. PMID: 26495371; PMCID: PMC4614567.
Copy Download .nbib Format: NLM
Share it on

Emerg (Tehran). 2014;2(4):151-7.

The Effect of Intrathecal Administration of Muscimol on Modulation of Neuropathic Pain Symptoms Resulting from Spinal Cord Injury; an Experimental Study.

Emergency (Tehran, Iran)

Marjan Hosseini, Zohreh Karami, Atousa Janzadenh, Seyed Behnamedin Jameie, Zahra Haji Mashhadi, Mahmoud Yousefifard, Farinaz Nasirinezhad

Affiliations

  1. Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  2. Basic Science Department, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
  3. Department of Basic Sciences, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran ; Physiology Research Center, Department of Physiology, Iran University of Medical Sciences, Tehran, Iran.
  4. Physiology Research Center, Department of Physiology, Iran University of Medical Sciences, Tehran, Iran.

PMID: 26495371 PMCID: PMC4614567

Abstract

INTRODUCTION: Neuropathic pain can be very difficult to treat and it is one of the important medical challenging about pain treatments. Muscimol as a new agonist of gamma-Aminobutyric acid receptor type A (GABAA) have been introduced for pain management. Thus, the present study was performed to evaluate the pain alleviating effect of intrathecal injection of different doses of muscimol as GABAA receptor agonist in spinal cord injury (SCI) model of neuropathic pain.

METHODS: In the present experimental study, male Wistar rats were treated by muscimol 0.01, 0.1 or 1 µg/10ul, intrathecally (i.t.) three weeks after induction of spinal cord injury using compression injury model. Neuropathic pain symptoms were assessed at before treatment, 15 minutes, one hour and three hours after muscimol administration. The time of peak effect and optimum dosage was assessed by repeated measures analysis of variance and analysis of covariance, respectively.

RESULTS: Muscimol with the dose of 0.01 µg in 15 minutes caused to improve the thermal hyperalgesia (df: 24, 5; F= 6.6; p<0.001), mechanical hyperalgesia (df: 24, 5; F= 7.8; p<0.001), cold allodynia (df: 24, 5; F= 6.96; p<0.001), and mechanical allodynia (df: 24, 5; F= 15.7; p<0.001). The effect of doses of 0.1 µg and 1 µg were also significant. In addition, the efficacy of different doses of muscimol did not have difference on thermal hyperalgesia (df: 24, 5; F= 1.52; p= 0.24), mechanical hyperalgesia (df: 24, 5; F= 0.3; p= -0.75), cold allodynia (df: 24, 5; F= 0.8; p= -0.56), and mechanical allodynia (df: 24, 5; F= 1.75; p= 0.86).

CONCLUSION: The finding of the present study revealed that using muscimol with doses of 0.01µg, 0.1µg, and 1 µg reduces the symptoms of neuropathic pain. In addition, the effect of GABAA agonist is short term and its effectiveness gradually decreases by time.

Keywords: GABAA receptor agonists; Neuropathic pain; muscimol; pain management

References

  1. Spinal Cord. 2013 Jul;51(7):564-70 - PubMed
  2. Anesthesiology. 2011 Feb;114(2):424-30 - PubMed
  3. Cochrane Database Syst Rev. 2013 Aug 29;(8):CD006146 - PubMed
  4. Neuropharmacology. 2011 Jul-Aug;61(1-2):121-32 - PubMed
  5. Brain Res Rev. 2009 Apr;60(1):202-13 - PubMed
  6. J Neurosci Methods. 1994 Jul;53(1):55-63 - PubMed
  7. Lancet Neurol. 2010 Aug;9(8):807-19 - PubMed
  8. Neuroscience. 2008 Jul 17;154(4):1539-53 - PubMed
  9. Anesth Analg. 2012 Mar;114(3):674-82 - PubMed
  10. Eur J Pain. 2013 Oct;17 (9):1327-37 - PubMed
  11. Pain Med. 2013 Oct;14(10):1477-96 - PubMed
  12. Br J Anaesth. 2013 Nov;111(5):711-20 - PubMed
  13. Pain. 1994 Dec;59(3):369-76 - PubMed
  14. Eur Rev Med Pharmacol Sci. 2013 Dec;17(23):3257-61 - PubMed
  15. Cochrane Database Syst Rev. 2014 Apr 27;(4):CD007938 - PubMed
  16. Expert Opin Drug Discov. 2010 May;5(5):441-60 - PubMed
  17. Curr Pain Headache Rep. 2014 Jan;18(1):388 - PubMed
  18. Pain. 2003 Sep;105(1-2):347-53 - PubMed
  19. Brain Res. 2007 Dec 14;1185:117-28 - PubMed
  20. Mol Cell Neurosci. 2003 Nov;24(3):818-30 - PubMed
  21. J Neurotrauma. 2012 Mar 20;29(5):898-904 - PubMed
  22. Anesthesiology. 2011 May;114(5):1144-54 - PubMed
  23. PLoS One. 2012;7(9):e45560 - PubMed
  24. Neuromodulation. 2013 Mar-Apr;16(2):114-20 - PubMed
  25. J Neurosci Methods. 2009 Oct 15;183(2):114-8 - PubMed
  26. Pain. 1988 Jan;32(1):77-88 - PubMed
  27. Curr Pain Headache Rep. 2012 Jun;16(3):207-16 - PubMed
  28. Cochrane Database Syst Rev. 2013 Nov 11;(11):CD010567 - PubMed
  29. Neurosci Lett. 2013 May 10;542:113-7 - PubMed
  30. Pain. 1983 Jun;16(2):109-10 - PubMed
  31. Pain Physician. 2013 Mar-Apr;16(2):E107-11 - PubMed
  32. Pain. 2013 Nov;154(11):2469-76 - PubMed
  33. Saudi J Anaesth. 2014 Jan;8(1):92-6 - PubMed
  34. Indian J Med Res. 2012 Mar;135:287-96 - PubMed

Publication Types